Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of $95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. Barclays Capital Inc., Piper Jaffray & Co., Cowen and Company, LLC, JMP Securities LLC, and Needham & Company, LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30 day option to purchase up to 710,526 additional shares.

Help employers find you! Check out all the jobs and post your resume.